Hostname: page-component-848d4c4894-r5zm4 Total loading time: 0 Render date: 2024-07-01T16:54:57.019Z Has data issue: false hasContentIssue false

Neuroendocrine carcinoma of the uterine cervix: 15-year experience from a tertiary care centre in Southern India

Published online by Cambridge University Press:  27 February 2020

Sobin V. Jacob
Affiliation:
Department of Radiation Oncology, Ida B Scudder Cancer Centre, Christian Medical College, Vellore, India
Arvind Sathyamurthy*
Affiliation:
Department of Radiation Oncology, Ida B Scudder Cancer Centre, Christian Medical College, Vellore, India
Jeba Karunya Ramireddy
Affiliation:
Department of Radiation Oncology, Ida B Scudder Cancer Centre, Christian Medical College, Vellore, India
Anitha Thomas
Affiliation:
Department of Gynecologic Oncology, Christian Medical College, Vellore, India
Kaalindi Singh
Affiliation:
Department of Radiation Oncology, Ida B Scudder Cancer Centre, Christian Medical College, Vellore, India
Thomas Samuel Ram
Affiliation:
Department of Radiation Oncology, Ida B Scudder Cancer Centre, Christian Medical College, Vellore, India
*
Author for correspondence: Arvind Sathyamurthy, Department of Radiation Oncology, Ida B Scudder Cancer Centre, Christian Medical College, Vellore, India. Tel: +919901294136. Email: dr.arvind.s.murthy@gmail.com

Abstract

Aim:

To analyse the presentation, treatment strategies and outcomes of neuroendocrine carcinoma of cervix treated with multi-modality approach at our institute.

Materials and methods:

The data of patients diagnosed to have cervical cancer between October 2004 and November 2018 were retrieved, and 14 patients of neuroendocrine carcinoma cervix who received treatment in our institution were identified. The patients were analysed based on demographic characteristics, disease stage, pathological characteristics, treatment and follow-up. The median overall survival and disease-free survival were calculated.

Results:

Median follow-up period was 8 months (range 1–52 months). Six patients died within 4 months of completion of treatment due to disease progression. Median overall survival was 12 months and median disease-free interval was 5·5 months. Four of the patients who underwent combined modality treatment consisting of neoadjuvant chemotherapy, concurrent chemoradiation therapy and brachytherapy are still on regular follow-up and are disease-free.

Conclusion:

Neuroendocrine carcinoma of the cervix is a rare but aggressive histological subtype. Combined modality approach with judicious use of systemic chemotherapy along with surgery and radiation therapy is essential for optimal outcomes.

Type
Original Article
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Clemens, BT, Iris, T, Askin, D, et al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature, BMC Cancer 2018; 18: 530.Google Scholar
Reagan, JW, Hamonic, MJ, Wentz, WB. Analytical study of the cells in cervical squamous-cell cancer. Lab Invest 1957; 6: 241250.Google ScholarPubMed
Albores-Saavedra, J, Poucell, S, Rodriguez Martinez, HA. Primary carcinoid of the uterine cervix. Pathologia 1972; 10: 185193.Google Scholar
Conner, MG, Richter, H, Moran, CA, Hameed, A, Albores-Saavedra, J. Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases. Ann Diagn Pathol 2002; 6: 345348.CrossRefGoogle ScholarPubMed
McCusker, ME, Coté, TR, Clegg, LX, Tavassoli, FJ. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol 2003; 88: 333339.CrossRefGoogle ScholarPubMed
Pecorelli, S, Zigliani, L, Odicino, F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009; 105: 107108.CrossRefGoogle ScholarPubMed
Potter, R, Haie-Meder, , C, Van Limbergen, , E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78: 6777.CrossRefGoogle Scholar
International Commission on Radiation Units and Measurements (ICRU). Dose And Volume Specification For Reporting Intracavitary Therapy In Gynecology, ICRU Report, 38. Bethesda MD: ICRU, 1985 Google Scholar
Viswanathan, AN, Deavers, MT, Jhingran, A, Ramirez, PT, Levenback, C, Eifel, PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004; 93: 2733. https://doi.org/10.1016/j.ygyno.2003.12.027.CrossRefGoogle ScholarPubMed
Delaloge, S, Pautier, P, Kerbrat, P, et al. Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. Clin Oncol (R Coll Radiol). 2000; 12: 357362.CrossRefGoogle Scholar
Hoskins, PJ, Swenerton, KD, Pike, JA, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol 2003; 21: 34953501.CrossRefGoogle Scholar
Chang, TC, Lai, CH, Tseng, CJ, Hsueh, S, Huang, KG, Chou, HH. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer 1998; 83: 712718.3.0.CO;2-V>CrossRefGoogle ScholarPubMed